Literature DB >> 24746824

Impeded Nedd4-1-mediated Ras degradation underlies Ras-driven tumorigenesis.

Taoling Zeng1, Qun Wang1, Jieying Fu1, Qi Lin1, Jing Bi1, Weichao Ding1, Yikai Qiao1, Sheng Zhang2, Wenxiu Zhao2, Huayue Lin1, Meilin Wang1, Binfeng Lu3, Xianming Deng1, Dawang Zhou1, Zhenyu Yin4, Hong-Rui Wang5.   

Abstract

RAS genes are among the most frequently mutated proto-oncogenes in cancer. However, how Ras stability is regulated remains largely unknown. Here, we report a regulatory loop involving the E3 ligase Nedd4-1, Ras, and PTEN. We found that Ras signaling stimulates the expression of Nedd4-1, which in turn acts as an E3 ubiquitin ligase that regulates Ras levels. Importantly, Ras activation, either by oncogenic mutations or by epidermal growth factor (EGF) signaling, prevents Nedd4-1-mediated Ras ubiquitination. This leads to Ras-induced Nedd4-1 overexpression, and subsequent degradation of the tumor suppressor PTEN in both human cancer samples and cancer cells. Our study thus unravels the molecular mechanisms underlying the interplay of Ras, Nedd4-1, and PTEN and suggests a basis for the high prevalence of Ras-activating mutations and EGF hypersignaling in cancer.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24746824     DOI: 10.1016/j.celrep.2014.03.045

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  29 in total

Review 1.  Posttranslational Modifications of RAS Proteins.

Authors:  Ian Ahearn; Mo Zhou; Mark R Philips
Journal:  Cold Spring Harb Perspect Med       Date:  2018-11-01       Impact factor: 6.915

Review 2.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

3.  NEDD4 is involved in acquisition of epithelial-mesenchymal transition in cisplatin-resistant nasopharyngeal carcinoma cells.

Authors:  Shaoyan Feng; Guangwei Yang; Haidi Yang; Zibin Liang; Rongkai Zhang; Yunping Fan; Gehua Zhang
Journal:  Cell Cycle       Date:  2017-04-05       Impact factor: 4.534

Review 4.  NEDD4: The founding member of a family of ubiquitin-protein ligases.

Authors:  Natasha Anne Boase; Sharad Kumar
Journal:  Gene       Date:  2014-12-17       Impact factor: 3.688

5.  Inhibition of NEDD4 inhibits cell growth and invasion and induces cell apoptosis in bladder cancer cells.

Authors:  Wu Wen; Jingying Li; Longwang Wang; Yifei Xing; Xuechao Li; Hailong Ruan; Xiaoqing Xi; Jianhua Xiong; Renrui Kuang
Journal:  Cell Cycle       Date:  2017-07-26       Impact factor: 4.534

6.  Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination.

Authors:  M Steklov; S Pandolfi; M F Baietti; A Batiuk; P Carai; P Najm; M Zhang; H Jang; F Renzi; Y Cai; L Abbasi Asbagh; T Pastor; M De Troyer; M Simicek; E Radaelli; H Brems; E Legius; J Tavernier; K Gevaert; F Impens; L Messiaen; R Nussinov; S Heymans; S Eyckerman; A A Sablina
Journal:  Science       Date:  2018-11-15       Impact factor: 47.728

Review 7.  Ubiquitin ligases in oncogenic transformation and cancer therapy.

Authors:  Daniela Senft; Jianfei Qi; Ze'ev A Ronai
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

8.  The HECT family of E3 ubiquitin ligases and PTEN.

Authors:  Min Sup Song; Pier Paolo Pandolfi
Journal:  Semin Cancer Biol       Date:  2021-06-12       Impact factor: 15.707

9.  NEDD4 regulates ubiquitination and stability of the cell adhesion molecule IGPR-1 via lysosomal pathway.

Authors:  Linzi Sun; Razie Amraei; Nader Rahimi
Journal:  J Biomed Sci       Date:  2021-05-07       Impact factor: 8.410

Review 10.  Post-translational modification of KRAS: potential targets for cancer therapy.

Authors:  Wei-Hua Wang; Tao Yuan; Mei-Jia Qian; Fang-Jie Yan; Liu Yang; Qiao-Jun He; Bo Yang; Jin-Jian Lu; Hong Zhu
Journal:  Acta Pharmacol Sin       Date:  2020-10-21       Impact factor: 7.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.